Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-08-06

FDA Approved: MAVYRET — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

FDA approved a supplemental application for MAVYRET (glecaprevir and pibrentasvir) submitted by AbbVie. The action approves a supplemental change to MAVYRET's l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Mavyret (glecaprevir/pibrentasvir)

Snippet

SUPPL AP for MAVYRET (GLECAPREVIR AND PIBRENTASVIR)